A Blenrep Comeback? Cancer Vaccine for Dogs; U.K. Snubs Enhertu

An interim analysis of the DREAMM-8 trial showed belantamab mafodotin (Blenrep) improved progression-free survival when combined with pomalidomide (Pomalyst) and dexamethasone as second-line treatment for patients with relapsed/refractory multiple myeloma, GSK announced. The drug was withdrawn from the U.S. market in 2022.

Common inherited genetic factors that predict cancer risk in the general population could also predict an elevated risk of new cancers in childhood cancer survivors. (Nature Medicine)

A study of children with sickle cell anemia showed that despite their elevated risk of infections and stroke, many don’t receive preventive care. (Pediatrics)

The FDA granted accelerated approval to zanubrutinib (Brukinsa) plus obinutuzumab (Gazyva) as a third-line option in follicular lymphoma based on findings from the phase II ROSEWOOD trial.

Medtronic announced that it received FDA clearance for its OsteoCool bone tumor ablation system.

The agency also expanded the approval of inotuzumab ozogamicin (Besponsa) to include the treatment of pediatric patients 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.

A vaccine may be able to delay or halt cancers in dogs. Could it one day be used for humans? (Yale News)

A cancer patient who was hit and dragged by a New York City bus and left partially paralyzed has been awarded $72.5 million by a city jury. (ABC News)

Why are more Asian-American women developing lung cancer despite never having smoked? (NBC News)

Bayer said it was victorious in a lawsuit brought by a retired postal service worker in Pennsylvania who alleged he developed non-Hodgkin lymphoma from using the company’s Roundup weedkiller. (Reuters)

The U.K.’s National Health Service is blocking the use of trastuzumab deruxtecan (Enhertu) for patients with advanced breast cancer after the National Institute for Health and Care Excellence said its cost outweighed its benefits. (The Independent)

Please enable JavaScript to view the

comments powered by Disqus.